Xylyx Bio, Inc.

NY Doing business as Xylyx Bio Inc.

UEI
N2N9KL2Y52X1
CAGE
7ZP58
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Small Business Joint Venture
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
760 Parkside Ave #321, Brooklyn, NY 11226, USA
Website
xylyxbio.com
Founded
2016
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

About Xylyx Bio, Inc.

Xylyx Bio, Inc. is a corporate entity registered in SAM.gov since July 2017, specializing in advanced bioengineering and tissue modeling technologies with a focus on developing innovative cell-based research platforms for medical research and drug development. The company is a for-profit organization located in Brooklyn, New York, that appears to be developing sophisticated bioengineered tissue models and platforms to address critical challenges in medical research, particularly in areas of organ transplantation, disease modeling, and drug discovery.

Through its federal grant awards, Xylyx Bio, Inc. has received multiple Small Business Innovation Research (SBIR) grants from prominent National Institutes of Health agencies, including the National Heart, Lung, and Blood Institute, the National Cancer Institute, and the National Institute of Diabetes and Digestive and Kidney Diseases. These grants have supported the development of highly specialized cell-based assay platforms for modeling complex medical conditions, such as lung fibrosis, liver fibrosis, and metastatic breast cancer. Specifically, the company has been developing innovative research platforms that integrate patient-derived cells with human extracellular matrix (ECM) to create physiologically-relevant in-vitro models. These platforms aim to improve drug testing and development by providing more accurate representations of disease environments, addressing significant gaps in current research methodologies. Notable projects include creating bioengineered human lung grafts, developing multi-organ metastatic breast cancer models, and generating liver fibrosis cell-based assay platforms that can potentially accelerate anti-fibrotic and anti-metastatic drug development.

Quick answers

What is Xylyx Bio, Inc.'s UEI?

Xylyx Bio, Inc.'s Unique Entity ID (UEI) in SAM.gov is N2N9KL2Y52X1.

What is Xylyx Bio, Inc.'s CAGE code?

Xylyx Bio, Inc.'s CAGE code is 7ZP58.

Where is Xylyx Bio, Inc. located?

Xylyx Bio, Inc.'s physical address in SAM.gov is 760 Parkside Ave #321, Brooklyn, NY 11226, USA.

Is Xylyx Bio, Inc. registered in SAM.gov?

Yes. Xylyx Bio, Inc.'s SAM.gov registration is active through March 23, 2027.

What is Xylyx Bio, Inc.'s most recent federal award?

Xylyx Bio, Inc.'s most recent federal grant award is Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation -… (R44HL182545), from National Heart Lung and Blood Institute, on September 8, 2025.

On GovTribe

See Xylyx Bio, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors